Latest Breaking News On - Nikhilc munshi - Page 1 : comparemela.com

Paving the Path to Progress in Multiple Myeloma Research

A fascination with laboratory research paired with hard work and dedication led to Nikhil C. Munshi, MD, becoming a pioneer in multiple myeloma treatment.

Little rockUnited statesRoberta kyleMehmetk samurNikhilc munshiMedha munshiKennethc andersonTarun srivastavaLawrence einhornMaharaja sayajirao universityJohns hopkins cancer centerSidney kimmel comprehensive cancer centerDana farber cancer instituteDrbc roy national awardMost distinguished lifetime achievement in myeloma researchInternational myeloma society

Kronos Bio Inc (KRON) Issues Pipeline Update and p300 KAT Inhibitor Development Candidate

Kronos Bio Inc (KRON) Issues Pipeline Update and p300 KAT Inhibitor Development Candidate
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Kronos bioNikhilc munshiChristopher dinsmoreNorbert bischofbergerKronos bio incJerome lipper multiple myeloma centerDana farber cancer

Dr Munshi on the Background of the CARTITUDE-1 Trial in Multiple Myeloma

Nikhil C. Munshi, MD, discusses the background of the phase 1b/2 CARTITUDE-1 trial of ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma and highlights the specific patient population enrolled in the study.

Nikhilc munshiDana farber cancer instituteMedicine at harvard medical schoolCorrelative scienceJerome lipper multiple myeloma centerKraft family chairMultiple myeloma immune effector cell therapyHarvard medical schoolMultiple myelomaOnclive tv

Dr Munshi on Implications of Findings From the CARTITUDE-1 Trial of Cilta-Cel in Myeloma

Dr Munshi on Implications of Findings From the CARTITUDE-1 Trial of Cilta-Cel in Myeloma
onclive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from onclive.com Daily Mail and Mail on Sunday newspapers.

Nikhilc munshiDana farber cancer instituteMedicine at harvard medical schoolCorrelative scienceJerome lipper multiple myeloma centerKraft family chairMultiple myeloma immune effector cell therapyHarvard medical school

Cilta-Cel Provides Sustained Efficacy and Safety in Relapsed/Refractory Multiple Myeloma

Nikhil C. Munshi, MD, discusses the significance of the FDA approval of cilta-cel in patients with multiple myeloma, shared the long-term findings from the pivotal CARTITUDE-1 trial, and highlighted future directions for CAR T-cell therapy in this disease.

United statesDana farber cancer instituteNikhilc munshiJerome lipper multiple myeloma centerHarvard medical schoolCorrelative scienceKraft family chairMultiple myeloma immune effector cell therapyAdaptive biotechnologiesKaryopharm therapeutics